Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and ...

Teva Pharmaceuticals USA Inc. (Teva USA) and Teva Neuroscience Inc. (“Teva”) agreed to pay $450 million to resolve two matters that allege ...

This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.

In this episode of Denatured, Lori and guests from Teva Pharmaceuticals and TOWER Capital review the investment landscape this year and the policies influencing investment heading into 2025.

On a bustling street corner one recent afternoon outside the offices of the Harm Reduction Action Center, employees of the ...

Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

Infertility Drugs MarketThe global infertility drugs market is set for significant growth over the next decade, with the ...

news PlayStation Creative, formerly Bungie Creative Studios, will continue to work on Destiny 2 and Marathon, as well as all over Sony live service games.